Kerendia Finerenone 28 Tablets contains the active ingredient finerenone at a concentration of 20 mg and is used for adults with chronic kidney disease (CKD) associated with type 2 diabetes.
Benefits and Uses of Kerendia Finerenone 20 Mg
Kerendia Finerenone is used for end stage kidney disease in adults with type 2 diabetes to:
-
Help slow the decline in kidney function.
-
It also helps lower the risk of death due to cardiovascular disease, non-fatal heart attacks, and hospitalization due to heart failure.
-
Kerendia’s effectiveness lies in its active ingredient finerenone, which reduces the effect of certain hormones that may damage the kidneys and heart.
-
It is specifically used to treat patients with stage 3 and 4 CKD who also have abnormally high levels of albumin in the urine.
Contraindications
-
Should not be used with strong CYP3A4 inhibitors.
-
Contraindicated in patients with adrenal gland insufficiency.
How to Use
-
Use exactly as prescribed by your doctor or pharmacist.
-
The maximum daily dose is one 20 mg tablet.
-
Take once daily, with or without food, at the same time each day.
-
Tablets can be swallowed with water. If swallowing is difficult, the tablet may be crushed and mixed with water or soft food (e.g., applesauce) and consumed immediately.
-
Do not take with grapefruit juice.
-
Dosage Determination:
-
Dosage is determined based on kidney function as assessed by a blood test.
-
Initial dose may be 10 mg or 20 mg daily.
-
After 4 weeks, a follow-up blood test is required to adjust the dose or discontinue the treatment based on the results.
Side Effects
-
Low sodium levels (may cause nausea, fatigue, headache, confusion, muscle weakness or cramps).
-
Decreased kidney function.
-
Increased uric acid in the blood.
-
Low blood pressure (may cause dizziness or fainting).
-
Itching.
Warnings and Precautions
-
Hyperkalemia (high potassium levels):
-
Kerendia may increase potassium levels, especially in patients with kidney impairment or risk factors.
-
Potassium and eGFR should be checked before starting treatment.
-
Do not initiate treatment if potassium levels exceed 5.0 mmol/L.
-
Potassium should be monitored regularly during treatment. In some cases, close monitoring may be required.
-
Breastfeeding:
-
Breastfeeding is not recommended during treatment and for 24 hours after the last dose.
-
Liver Impairment:
-
Kerendia is contraindicated in severe liver impairment (Child-Pugh C) and potassium levels should be monitored in moderate impairment (Child-Pugh B).
Drug Interactions
-
Strong CYP3A4 inhibitors:
-
Do not use with Kerendia. Avoid grapefruit and grapefruit juice.
-
Moderate or weak CYP3A4 inhibitors:
-
Monitor potassium levels when starting or adjusting the dose. Adjust Kerendia dosage if needed.
-
Strong or moderate CYP3A4 inducers:
-
Concurrent use should be avoided.
Storage
-
Store at a cool, dry place.
-
Keep out of reach of children.
Kerendia Finerenone 20 Mg Ingredients
-
Active Ingredient:
-
Finerenone (20 mg per tablet).
-
Other Ingredients:
-
Cellulose.
-
Lactose.
-
Sodium.
-
Coloring agents (yellow iron oxide).
-
Additional ingredients for tablet core and coating.